Predictors of response to tofacitinib or etanercept in a phase 3 randomized, noninferiority study in patients with moderate to severe chronic plaque psoriasis

被引：0

作者：

Lambert, Jo ^{[1
]}

Strohal, Robert ^{[2
]}

de la Cruz, Claudia ^{[3
]}

Thaci, Diamant ^{[4
]}

Bachelez, Herve ^{[5
]}

Iversen, Lars ^{[6
]}

Rottinghaus, Scott ^{[7
]}

Tallman, Anna ^{[8
]}

Tan, Huaming ^{[7
]}

Berstein, Gabriel ^{[9
]}

机构：

[1] Ghent Univ Hosp, Ghent, Belgium

[2] Fed Acad Teaching Hosp Feldkirch, Feldkirch, Austria

[3] Clin Dermacross, Santiago, Chile

[4] Univ Med Sch, Comprehens Ctr Inflammat Med, Schleswig Holstein Campus, Lubeck, Germany

[5] Univ Paris Diderot, Sorbonne Paris Cite, Hop St Louis, AP HP, Paris, France

[6] Aarhus Univ Hosp, Aarhus C, Denmark

[7] Pfizer Inc, Groton, CT USA

[8] Pfizer Inc, New York, NY USA

[9] Pfizer Inc, Cambridge, MA USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

3386

引用

页码：AB263 / AB263

页数：1

共 50 条

[1] Predictors of response to tofacitinib or etanercept in a Phase 3 randomised, non-inferiority study in patients with moderate to severe chronic plaque psoriasis
Lambert, J.
Strohal, R.
de la Cruz, C.
Thaci, D.
Bachelez, H.
Iversen, L.
Rottinghaus, S.
Tallman, A.
Tan, H.
Berstein, G.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 78 - 78
[2] Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study
Valenzuela, F.
Paul, C.
Mallbris, L.
Tan, H.
Papacharalambous, J.
Valdez, H.
Mamolo, C.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (10) : 1753 - 1759
[3] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial
Bissonnette, R.
Iversen, L.
Sofen, H.
Griffiths, C. E. M.
Foley, P.
Romiti, R.
Bachinsky, M.
Rottinghaus, S. T.
Tan, H.
Proulx, J.
Valdez, H.
Gupta, P.
Mallbris, L.
Wolk, R.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 37 - 37
[4] Tofacitinib exposure-response characteristics in patients with moderate to severe chronic plaque psoriasis
Gupta, Pankaj
Hutmacher, Matthew
Papp, Kim
Lebwohl, Mark
Ito, Kaori
Tan, Huaming
Wolk, Robert
Mebus, Charles
Rottinghausi, Scott T.
Valdez, Hernan
Mallbris, Lotus
Krishnaswami, Sriram
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S8 - S8
[5] A PHASE 3, MULTICENTER, RANDOMIZED STUDY COMPARING USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
Griffiths, C.
Strober, B.
van der Kerkhof, P. C. M.
Ho, V
Guzzo, C.
Yeilding, N.
Fidelus-Gort, R.
Zhou, B.
Xia, K.
Menter, A.
ACTA DERMATO-VENEREOLOGICA, 2009, 89 (05) : 584 - 585
[6] EXPOSURE-RESPONSE CHARACTERISTICS AND PREDICTORS OF EFFICACY IN MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS PATIENTS RECEIVING TOFACITINIB.
Hutmacher, M. M.
Papp, K. A.
Lebwohl, M.
Ito, K.
Tan, H.
Wolk, R.
Mebus, C.
Rottinghaus, S.
Valdez, H.
Krishnaswami, S.
Gupta, P.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S52 - S52
[7] PREDICTORS OF RESPONSE TO TILDRAKIZUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Blauvelt, Andrew
Reich, Kristian
Papp, Kim A.
Tyring, Stephen K.
Sinclair, Rodney
Thaci, Diamant
Gooderham, Melinda
Li, Qing
Cichanowitz, Nicole
La Rosa, Carmen
ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 22 - 22
[8] Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
Bachelez, Herve
van de Kerkhof, Peter C. M.
Strohal, Robert
Kubanov, Alexey
Valenzuela, Fernando
Lee, Joo-Heung
Yakusevich, Vladimir
Chimenti, Sergio
Papacharalambous, Jocelyne
Proulx, James
Gupta, Pankaj
Tan, Huaming
Tawadrous, Margaret
Valdez, Hernan
Wolk, Robert
LANCET, 2015, 386 (9993): : 552 - 561
[9] Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis
Ma, Guangli
Xie, Rujia
Strober, Bruce
Langley, Richard
Ito, Kaori
Krishnaswami, Sriram
Wolk, Robert
Valdez, Hernan
Rottinghaus, Scott
Tallman, Anna
Gupta, Pankaj
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (06): : 587 - 596
[10] Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis
Blauvelt, Andrew
Reich, Kristian
Papp, Kim A.
Tyring, Stephen K.
Sinclair, Rodney
Thaci, Diamant
Gooderham, Melinda
Li, Qing
Cichanowitz, Nicole
la Rosa, Carmen
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB226 - AB226

← 1 2 3 4 5 →